GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2007

Pro-Pharmaceuticals and Digna to Enhance Hep C Therapeutics

  • Pro-Pharmaceuticals will apply its carbohydrate technology platform to Digna Biotech’s drugs to achieve improved treatment of chronic hepatitis C infections.

    "The collaboration with Digna is an important step in the development, commercialization, and validation of our first-in-class carbohydrate technology," notes David Platt, Ph.D., president and CEO, Pro-Pharmaceuticals.

    Pro-Pharmaceuticals' Davanat® will be the first to be checked as data from preclinical and clinical trials show that Davanat increased the patient's exposure to 5-FU 10-fold with no increase in toxicity.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?